37 completed, 9 terminated, 7 active not recruiting, 3 recruiting. 58 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 58 | Completed 37, Terminated 9, Active not recruiting 7, Recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| 64Cu-GRIP B in Patients With Advanced Malignancies Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET) - Prostate Cancer, Renal Cancer | Phase 1 / Phase 2 | Recruiting | Rahul Aggarwal | 91 | 2023-05-25 | 2026-03-17 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-11-12 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-11-12 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Atezolizumab, Guadecitabine - Urothelial Carcinoma | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 21 | 2017-11-27 | 2021-11-04 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer enfortumab vedotin (EV), pembrolizumab, cisplatin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Terminated | Astellas Pharma Global Development, Inc. | 348 | 2017-10-11 | 2026-03-24 |
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Enfortumab vedotin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 2 | Completed | Astellas Pharma Inc | 219 | 2017-10-08 | 2024-08-27 |
| Afatinib in Advanced Refractory Urothelial Cancer afatinib dimaleate, laboratory biomarker analysis - Distal Urethral Cancer, Proximal Urethral Cancer | Phase 2 | Terminated | University of Chicago | 32 | 2017-09-13 | 2025-04-25 |
| LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Crizotinib - Urinary Bladder Neoplasms, Ureteral Neoplasms | Phase 2 | Terminated | Wake Forest University Health Sciences | 8 | 2016-09-27 | 2022-11-03 |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Eribulin Mesylate, Gemcitabine Hydrochloride - Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2014-12-11 | 2019-12-16 |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Vinflunine, Gemcitabine, Carboplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Dr Anders Ullén | 62 | 2014-04-01 | 2019-10-08 |
| Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer cisplatin, gemcitabine hydrochloride, methotrexate - Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Withdrawn | University of Southern California | 2013-05-01 | 2014-01-29 | |
| Cabozantinib for Advanced Urothelial Cancer Cabozantinib - Urothelial Carcinoma, Urethral Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 69 | 2012-09-11 | 2022-10-18 |
Showing 20 of 58. Sign in to see all of them.
Urinary Bladder Neoplasms (53) · Ureteral Neoplasms (25) · Carcinoma, Transitional Cell (13) · Carcinoma, Renal Cell (2) · Kidney Neoplasms (2) · Neoplasms (2) · Penile Neoplasms (2) · Prostatic Neoplasms (2) · Urachal adenocarcinoma (2) · Urachal cancer (2) · Urologic Neoplasms (2) · Adrenal Gland Neoplasms (1) · Anus Neoplasms (1) · Biliary Tract Neoplasms (1)
Female Urogenital Diseases (58) · Female Urogenital Diseases and Pregnancy Complications (58) · Male Urogenital Diseases (58) · Urethral Diseases (58) · Urogenital Diseases (58) · Urologic Diseases (58) · Neoplasms by Site (57) · Urogenital Neoplasms (57) · Neoplasms (56) · Urologic Neoplasms (56) · Urinary Bladder Diseases (53) · Ureteral Diseases (25) · Neoplasms by Histologic Type (16) · Carcinoma (15) · Neoplasms, Glandular and Epithelial (15)
Gemcitabine (19) · Cisplatin (12) · Carboplatin (6) · Paclitaxel (6) · Nivolumab (5) · Fluorouracil (4) · Doxorubicin (3) · Magnetic Resonance Spectroscopy (3) · Radiotherapy (3) · Specimen Handling (3) · Sunitinib (3) · atezolizumab (3) · Biopsy (2) · CTLA-4 Antigen (2) · Docetaxel (2)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (6) · SWOG Cancer Research Network (6) · Eastern Cooperative Oncology Group (4) · Cardiff University (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Memorial Sloan Kettering Cancer Center (2) · Achieve Life Sciences (1) · Altor BioScience (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Dendreon (1) · Dr Anders Ullén (1) · Eli Lilly and Company (1)
United States (42) · Spain (7) · United Kingdom (7) · Italy (6) · Canada (5) · France (5) · Netherlands (5) · Germany (4) · Puerto Rico (3) · South Africa (3) · Belgium (2) · Brazil (2) · Denmark (2) · Israel (2) · Japan (2)
Daniel P. Petrylak, MD (2) · Dean F. Bajorin, MD (2) · Robert Dreicer (2) · Robert Dreicer, MD, FACP (2) · Andrea B Apolo (1) · Andrea B Apolo, M.D. (1) · Andrea Necchi, MD (1) · Anishka A D'Souza (1) · Arif Hussain (1) · Arlene Siefker-Radtke (1) · Arlene Siefker-Radtke, MD (1) · Bruce J. Roth, MD (1) · Camila MV Moniz, Doctor (1)
PMID 12448661, PMID 12767086, PMID 15911238, PMID 18459175, PMID 18501081, PMID 19269798, PMID 19371909, PMID 19786668, PMID 22162575, PMID 22819172, PMID 23329066, PMID 25427282, PMID 26149529, PMID 26582660, PMID 26926681, PMID 31356140, PMID 31390274, PMID 31648851, PMID 32645282, PMID 33991512, PMID 34030643, PMID 35031545, PMID 35168844, PMID 35537412, PMID 36041086, PMID 37328287, PMID 37369081, PMID 38215355, PMID 38849479
U10CA032102 (6), U10CA031946 (3), U10CA021115 (2), 2017 (1), N01CM00038 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA014599 (1), P30CA015704 (1), P30CA016672 (1), P30CA093373 (1), P30CA138292 (1), P50CA091846 (1), R01CA229354 (1)